AstraZeneca (AZN)
(Real Time Quote from BATS)
$76.92 USD
+0.60 (0.79%)
Updated May 8, 2024 12:59 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
AZN 76.92 +0.60(0.79%)
Will AZN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AZN
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
Why Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights AstraZeneca, Qualcomm, FedEx, American International and Baker Hughes
Top Analyst Reports for AstraZeneca, QUALCOMM & FedEx
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Other News for AZN
What You Missed On Wall Street This Morning
AstraZeneca withdraws COVID-19 vaccine
GLOBAL BROKER RATINGS: Deutsche Bank cuts UBS; JP raises TeamViewer
AstraZeneca is withdrawing COVID shot worldwide due to vaccine glut
An Update On Ascendis Pharma's Path To Profitability